SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 7, 2004
LIGAND PHARMACEUTICALS INCORPORATED
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
000-20720
(Commission File Number)
10275 SCIENCE CENTER DRIVE,
SAN DIEGO, CALIFORNIA
(Address of principal executive offices)
(858) 550-7500
(Registrant's telephone number, including area code)
77-0160744
(I.R.S. Employer Identification No.)
92121-1117
(Zip Code)
Item 8.01 Other Events
On December 7, 2004, Martin D. Meglasson, our Vice President of Discovery
Research, amended his two previously- executed stock selling plans dated
November 29, 2004. Under those plans, Dr. Meglasson authorized the sale of up to
6,859 and 6,860 shares, respectively, that were purchased on the open market or
are subject to an option granted by the Company on February 26, 2004. In order
to avoid any potential "short-swing profit" liability under section 16 of the
Securities Exchange Act of 1934, the amendment changes the starting date for
stock sales under the plans from April 1, 2005 to May 12, 2005 and changes the
end date from November 1, 2005 to November 12, 2005.
Item 9.01 Exhibits
EXHIBIT NUMBER DESCRIPTION
99.1 Letter Amendment
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has caused this report to be signed on its behalf by the
undersigned.
LIGAND PHARMACEUTICALS INCORPORATED
Date : December 7, 2004 By: /S/WARNER R. BROADDUS
Name: Warner R. Broaddus
Title: Vice President, General Counsel & Secretary